糖尿病、内分泌和肾脏疾病

Our unique perspective shapes possibilities in diabetes clinical research

我们的内分泌专家将利用他们在糖尿病和血脂异常方面的丰富经验，帮助您制定精简高效的解决方案。无论您是小型生物技术公司还是大型制药公司，我们均竭诚与您合作，帮助您实现特定的研发目标。

我们针对糖尿病和内分泌药物研发提供一整套的全面解决方案。 From lead optimization through commercialization, we are personally invested in maximizing the return on investment of your development program.

Finding the diabetes cure faster

随着糖尿病患者日益增多，寻找治愈良方的竞争也愈演愈烈。我们专攻治疗领域的专家可以利用专为您定制的成熟策略，帮您加快进程，更快实现研发目标。让我们助您率先到达终点。

• 利用临床前试验作用机制研究，更快作出更明智的临床决策。

• Quantify insulin secretion with customized glucose clamps in healthy normal volunteers and/or patients with Type 1 or Type 2 diabetes 

• Speed up timelines by integrating preclinical safety assessments with proof-of-concept studies

• 利用我们在全球大型心血管试验方面的丰富经验和运作能力，提供终点裁定。

• Start the right trials, pre-IND, and accelerate your market approval by incorporating market access and regulatory strategies into early phase designs

In endocrine studies, including diabetes, results depend on comprehensive testing solutions—from the lab to the clinic. We help you achieve success by ensuring fully standardized methodology across all of our five global National Glycohemoglobin Standardization Program Level 1 certified central laboratories, to provide you with exceptionally accurate worldwide data for A1C testing. Couple our testing leadership with our proprietary Xcellerate^® knowledge base that helps you optimize site selection and recruitment, and you’ll have a diabetes program that works harder for you. 

Revealing new opportunities to grow your business

我们和您一样热爱科学。从探索2型糖尿病药物在治疗1型糖尿病方面的新功效，到积极寻求生物制剂、生物仿制药、设备及新颖胰岛素给药系统的潜在机遇，我们始终掌握着糖尿病和内分泌药物研发领域的尖端技术。我们的目标是提供能帮助您走向成功的Solutions Made Real^®解决方案。

与糖尿病或内分泌专家联系

如果您有问题想联系我们的糖尿病/内分泌学专家，请点击下面的按钮。

Barry J. Goldstein，医学博士，美国内分泌学院院士
副总裁兼全球治疗领域负责人

Barry Goldstein博士于2013年加入徕博科，担任心血管、代谢、糖尿病、内分泌和肾脏疾病全球治疗领域主管。他是经专业认证的内分泌和糖尿病医生，在学术界和业界拥有超过25年的临床和基础研究经验。

他的丰富经验包括在杰弗逊医学院建立了强大的II-IV期糖尿病和内分泌临床试验研究单位，作为主研究者（PI）或者联合主研究者开展了近100项临床试验。 Dr. Goldstein is also recognized leader in diabetes research and clinical practice; he is a past associate editor of Diabetes and the Journal of Clinical Endocrinology & Metabolism and has served on many grant review panels for National Institutes of Health, American Diabetes Association and JDRF, as well as industry scientific advisory panels. 他发表过超过220篇论文、社论、专题研究、教科书章节以及担任联合编辑的文献。

Barbara S. Gillespie（医学博士、MMS、FASN）
徕博科肾脏疾病部门副总裁兼治疗主管
北卡罗来纳大学医学院肾病和高血压部门客座教授

Dr. Gillespie joined Labcorp in 2017 after over a decade of leadership experience at Quintiles, where she held a variety of positions, including working in the Office of the Chief Medical and Scientific Officer, serving as Global Therapeutic Lead for Nephrology and also as North American Head of the U.S. Internal Medicine team. 她目前获得了肾脏病专业认证。

 Dr. Gillespie serves on the board of directors of the Kidney Health Initiative as well as on the scientific advisory board for National Kidney Foundation Chronic Kidney Disease Registry. She is on the stakeholder committee and an invited participant for Food and Drug Administration/European Medical Association/National Kidney Foundation workshop on renal endpoints (March 2018). 凭借广泛的肾脏病学领域经验，Gillespie博士目前在位于北卡罗来纳州罗利的NaphCare担任肾病和透析服务副医疗主管。

Jennifer Ennis，医学博士
Medical Director, Litholink Corporation

Joining Litholink in 2009, Dr. Jennifer Ennis has overseen the medical and clinical aspects of Labcorp’s clinical decision support tools for management of chronic kidney disease, cardiovascular disease and diabetes.

Ennis博士是专业认证内科和肾病医生，同时也是伊利诺伊大学芝加哥分校肾脏医学部门的临床助理教授。除了临床和教学职责以外，她还从事慢性肾脏疾病的临床研究，并撰写了多篇摘要和经过同行评审的出版物。